Like Symphony Health Solutions

announced 8/8/2017 via GlobeNewswire

PRA Health Sciences, will acquire Symphony Health Solutions

synopsis: PRA Health Sciences, Inc. (“PRA”), a leading clinical research organization, announced it has signed a definitive agreement to acquire Symphony Health Solutions Corporation (“Symphony Health”), a privately-held best-in-class provider of data, analytics and consulting solutions to the life sciences market.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: Symphony Technology Group
target: Symphony Health Solutions
Symphony Health Solutions is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth.
price ($mm)
$530
rev ($mm)
$200
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 6/1/2011 via PR Newswire

Wolters Kluwer Health, acquired Lexi-Comp, Inc.

synopsis: Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry, has completed its acquisition of Lexi-Comp, Inc., a leading global provider of drug information and clinical content for pharmacists and clinicians.
buyer parent: Wolters Kluwer NV
buyer: Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Its customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. "
target: Lexi-Comp, Inc.
Lexicomp is an industry-leading provider of drug information and clinical content for the healthcare industry. The company provides the tools necessary to help improve patient safety, ensure compliance, and elevate the quality of care patients receive.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/19/2019 via BusinessWire

Audax Group, acquired Corrona, Inc.

synopsis: Audax Private Equity announced that it has recapitalized, in partnership with the management team, Corrona, LLC. Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators.
buyer: Audax Group
Audax Group is a leading alternative investment manager with offices in Boston, New York, and San Francisco. Since its founding in 1999, the firm has raised over $24 billion in capital across its Private Equity and Private Debt businesses. "
target parent: Great Point Partners
target: Corrona, Inc.
Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/10/2009 via BusinessWire

United BioSource Corporation, acquired Cognitive Drug Research, Ltd.

synopsis: United BioSource Corporation (UBC) announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Cognitive Drug Research, Ltd.
Cognitive Drug Research, Ltd. (CDR) is the world leader in automated cognitive function assessment in phase I through phase IV clinical trials. Founded by Keith Wesnes in 1986, CDR’s proprietary cognitive assessment system can be administered to virtually any patient population in any environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2016 via BNC Analysis

M3, Inc., will acquire Vidal Group

synopsis: Electra Partners’ portfolio company AXIO Group has received a binding offer from M3 Inc. to purchase Vidal Group, a European provider of reference drug information. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients with on-line access to up-to-date drug databases and related treatment-based information.
buyer: M3, Inc. (TSE:2413:$1,110.45)
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet. "
target parent: Electra Partners LLP
target: Vidal Group
Vidal Group is a leading European healthcare informatics and information systems company. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients across Europe with on-line access to up-to-date drug databases and related treatment-based information.
price ($mm)
$133
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/4/2011 via Company Press Release

Elsevier B.V., acquired Shanghai Datong Medical Information Technology Co., Ltd.

synopsis: Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced the acquisition of Shanghai Datong Medical Information Technology Co., Ltd., a leading drug decision support provider in China.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals and close to 20,000 book titles. "
target: Shanghai Datong Medical Information Technology Co., Ltd.
Shanghai Datong Medical Information Technology Co., Ltd. is a drug decision support provider in China. Datong's flagship product 'Clinical Drug Consultation and Safety Monitoring System' is embedded in the hospital's computerised physician order system.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/20/2010 via PR Newswire

Wolters Kluwer Health, acquired Pharmacy OneSource, Inc.

synopsis: Wolters Kluwer Health, a leading provider of information and business intelligence for professionals, students and institutions announced it has completed the acquisition of Pharmacy OneSource, a leading Software-as-a-Service (SaaS) provider in the healthcare industry.
buyer parent: Wolters Kluwer NV
buyer: Wolters Kluwer Health
Wolters Kluwer Health is a leading provider of information for professionals and students in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Major brands include traditional publishers of medical and drug reference tools and textbooks. "
target: Pharmacy OneSource, Inc.
Pharmacy OneSource is healthcare's #1 Software-as-a-Service (SaaS) provider. Their more than 80 innovative team members provide best-in-class, SaaS solutions to current and future challenges within health-systems worldwide.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/9/2017 via PR Newswire

The WIRB-Copernicus Group, acquired MedAvante, Inc.

synopsis: WIRB-Copernicus Group® (WCG™), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, announced that it has acquired MedAvante. MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in global clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: MedAvante, Inc.
MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in clinical trials. With Virgil™, its electronic clinical outcome assessment (eCOA) platform, clinical research sponsors are able to maximize outcome data quality & increase operational efficiency.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 2/13/2013 via BNC Analysis

MedBox, Inc., will acquire BioScriptRx

synopsis: Medbox, a developer of medical marijuana dispensing systems, has announced that it will take possession of the ownership stake in Bio-Tech Medical, creator of BioScriptRx, a biometric, real-time, anonymous prescription monitoring database designed to protect patient privacy and law enforcement intelligence.
buyer: MedBox, Inc.
MedBox features patented systems that dispense medication to individuals based on biometric identification. Their systems allow pharmacies, assisted living facilities, prisons, hospitals, doctors’ offices, and alternative medicine clinics to help manage employee possession of sensitive drugs. "
target: BioScriptRx
Bio-Tech Medical was founded in 2007 and is a creator of BioScriptRx, a biometric, real-time, anonymous prescription monitoring database designed to protect patient privacy and law enforcement intelligence.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/1/2018 via Company Press Release

BioInformatics Inc., acquired Kalorama Information

synopsis: BioInformatics Inc., the premier research and advisory company serving the life science industry, has acquired Kalorama Information from MarketResearch. Kalorama Information is a leading publisher of market research in healthcare areas, including in vitro diagnostics, imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.
buyer: BioInformatics Inc.
BioInformatics Inc. is the leading research and advisory firm serving the life science, diagnostic and analytical instrument industries. Their expertise includes assessing the size and attractiveness of markets, optimizing product configurations and pricing and validating corporate acquisitions. "
target parent: MarketResearch.com, Inc.
target: Kalorama Information
Kalorama Information is a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals. Kalorama only publishes in healthcare.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/6/2017 via Company Press Release

The Access Group, acquired Health Strategies Group

synopsis: Water Street Healthcare Partners, through its subsidiary, The Access Group, has acquired Health Strategies Group. Health Strategies Group is the leader in market access intelligence and customized research for pharmaceutical and biotech professionals. It dissects trends and identifies opportunities to help companies optimize their product access.
buyer parent: Water Street Healthcare Partners
buyer: The Access Group
The Access Group offers a breadth of services to clients, from traditional “block-and-tackle” launch execution tactics to in-depth market assessments. The company is dedicated to complete product life cycle management, creating brand solutions that drive demand across multiple stakeholder channels. "
target: Health Strategies Group
Health Strategies Group offers a dedicated team of research leaders committed to dissecting the trends, identifying customer needs, and pinpointing the barriers and opportunities for biopharma within the evolving health care environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2015 via PR Newswire

Insignia Capital Group, acquired Metanexgen, Inc.

synopsis: Insignia Capital Group announced the acquisition of metanexgen from DFW Capital Partners. Based in Bensalem, PA, metanexgen is a provider of technology-enabled multi-channel marketing solutions that allow pharmaceutical, biotechnology and medical device brands to effectively market their products to healthcare practitioners.
buyer: Insignia Capital Group
Insignia Capital is a private equity firm working with lower-middle market companies. Insignia Capital works with a wide variety of companies but their specialty is consumer, business services and healthcare. "
target parent: DFW Capital Partners
target: Metanexgen, Inc.
Metanexgen is a provider of technology-enabled multi-channel marketing solutions that allow pharmaceutical, biotechnology and medical device brands to effectively market their products to healthcare practitioners.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/12/2014 via Company Press Release

Everyday Health, Inc., will acquire DoctorDirectory.com

synopsis: Everyday Health signed a definitive agreement to acquire DoctorDirectory. Based in North Carolina, DoctorDirectory provides pharmaceutical companies with multi-channel marketing services that target healthcare professionals. DoctorDirectory.com, Inc. also operates as an online directory for finding a doctor by specialty.
buyer: Everyday Health, Inc. (EVDY:$253.92)
Everyday Health, Inc. is a provider of digital health and wellness solutions. They attract consumers and healthcare professionals to their health and wellness properties, and utilize their data and analytics to deliver personalized content experiences and marketing and engagement solutions. "
target: DoctorDirectory.com
DoctorDirectory.com, Inc. operates as an online directory for finding a doctor by specialty. They also provide Healthcare Professionals the opportunity to participate in Market Research and other programs that help shape the healthcare industry.
price ($mm)
$65
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/16/2014 via Company Press Release

BioPharm Communications, LLC, acquired Carson Analytics

synopsis: BioPharm Communications, a portfolio company of Southfield Capital and minority shareholder Boathouse Capital has announced the acquisition of Carson Analytics. Carson Analytics is a leading provider of integrated commercial analytics solutions for the pharmaceutical and biotechnology industries.
buyer parent: Southfield Capital Advisors
buyer: BioPharm Communications, LLC
BioPharm develops promotional medical education programs for customers in the pharmaceutical and biotechnology industries. The company creates robust clinical content in collaboration with key opinion leaders and delivers it to healthcare practitioners through the company's comprehensive suite. "
target: Carson Analytics
Carson Analytics is a leading provider of integrated commercial analytics solutions for the pharmaceutical and biotechnology industries. They provide advanced analytics solutions including forecasting, promotion response analysis and optimization of promotion mix.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/28/2013 via BusinessWire

QPharma, Inc., acquired MD Mindset, LLC

synopsis: QPharma has announced its acquisition of MD Mindset, LLC, a leading physician research firm focused on improving pharmaceutical sales force and marketing effectiveness. The Atlanta, GA-based company will transition operations of MD Snapshot, MD Feedback, MD Fellowship, and iSFE Tracker products and services to Morristown, New Jersey.
buyer: QPharma, Inc.
QPharma provides regulatory compliance and brand support for the pharmaceutical, medical device and other life sciences industries. Sample services include remediation consulting, validation services, project management & auditing, aggregate spend reporting, sample accountability & online training. "
target: MD Mindset, LLC
MD Mindset, founded in 2001, was established to help pharmaceutical and life sciences sales professionals maximize their performance and effectiveness when calling on healthcare professionals for sales details.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/23/2012 via BusinessWire

ImpactRx, Inc., acquired AlphaDetail, Inc.

synopsis: ImpactRx, a Symphony Technology Group company, and the pioneer in measuring the impact of promotion on physicians’ attitudes and prescribing behavior, announced that it has acquired AlphaDetail, Inc., a leader in global healthcare primary market research and influence network mapping.
buyer parent: Symphony Technology Group
buyer: ImpactRx, Inc.
ImpactRx is the leading provider of consultative and analytically-based promotional effectiveness solutions to the healthcare industry. ImpactRx's ImpactData™ is the industry’s sole source of continuous-capture market promotion and physician treatment data. "
target: AlphaDetail, Inc.
AlphaDetail is a rapidly growing global market research consulting company focused on the pharmaceutical and biotechnology industry. It uses the Internet as a channel to enable rapid, convenient, and effective communication between pharmaceutical companies, healthcare professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/28/2016 via BNC Analysis

AplusA, acquired Bell Falla & Associates LLC

synopsis: AplusA buys Bell Falla to become a leading international marketing research for the pharmaceutical industry and the health sector. Bell Falla is an international market research and consulting firm for pharmaceutical, biotech and medical device companies. With the acquisition, AplusA plans to establish itself as a major player in the global market.
buyer: AplusA
AplusA is a reputable medical market research firm that specializes in international, primary research for the Pharmaceutical, Biotechnology and Medical Device Industries. For over 25 years, AplusA has been guiding lifecycle management of the most innovative healthcare products worldwide. "
target: Bell Falla & Associates LLC
Bell Falla & Associates is an international market research and consulting firm for pharmaceutical, biotech and medical device companies. They provide both qualitative and quantitative research using state of the art research methodologies, as well as statistical consulting and marketing consulting.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/7/2013 via BNC Analysis

Informa Healthcare, acquired Elsevier Business Intelligence

synopsis: Informa plc has acquired Elsevier Business Intelligence. Elsevier Business Intelligence was cobbled together from previous Elsevier acquisitions—F-D-C Reports, Inc. in 1994 and Windhover Information, Inc. in 2008. It publishes some of the most prestigious newsletters for the healthcare industry.
buyer parent: Informa plc
buyer: Informa Healthcare
Informa Healthcare is a medical and scientific publisher whose goal is to connect librarians, scientists, professionals and other medical practicioners with information they can trust and see through a comprehensive portfolio of journals, print and online books, encyclopedias and directories. "
target parent: Reed Elsevier
target: Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. It provides publications, conferences, databases and reports.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/26/2005 via PR Newswire

Greenfield Online, Inc., acquired Rapidata.net, Inc.

synopsis: Greenfield Online, Inc SRVY, a leading provider of Internet survey solutions to marketing research and consulting companies, today announced it has completed the acquisition of Rapidata.net, Inc., a privately-held North Carolina corporation, for $5.5 million in cash, subject to certain post closing adjustments.
buyer: Greenfield Online, Inc. (SRVY:$0.00)
Greenfield Online, Inc. is a global interactive media and services company that collects consumer attitudes about products and services, enabling consumers to reach informed purchasing decisions about the products and services they want to buy; and helping companies better understand their customer."
target: Rapidata.net, Inc.
Founded fifteen years ago by research pharmacist and professor David P. Lipson, R.PH., Ph.D., Rapidata.net connects pharmaceutical market researchers to healthcare providers and their patients. This connection allows pharmaceutical market researchers to learn more about the prescription medications
price ($mm)
$5.50
rev ($mm)
$2
EBITDA ($mm)
EV / rev
2.6x
EV / EBITDA
closed 12/9/2015 via BNC Analysis

IMS Health Incorporated, acquired IASIST, S.A.

synopsis: IMS Health, a leading global information and technology services company, has acquired IASIST, an added value, professional service company which offers health care providers, payers and the health industry the clinical and economic information required to improve quality and efficiency in their organizations.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is an information and technology services company providing clients in the healthcare industry with solutions to measure and improve their performance. The company's IMS One™ cloud platform provides comprehensive insights into diseases, treatments, costs and outcomes. "
target: IASIST, S.A.
Iasist is an added value, professional service company which offers health care providers, payers and the health industry the clinical and economic information required to improve quality and efficiency in their organisations and the services provided to their customers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/8/2017 via GlobeNewswire

PRA Health Sciences, will acquire Symphony Health Solutions

synopsis: PRA Health Sciences, Inc. (“PRA”), a leading clinical research organization, announced it has signed a definitive agreement to acquire Symphony Health Solutions Corporation (“Symphony Health”), a privately-held best-in-class provider of data, analytics and consulting solutions to the life sciences market.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: Symphony Technology Group
target: Symphony Health Solutions
Symphony Health Solutions is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth.
price ($mm)
$530
rev ($mm)
$200
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/8/2017 via GlobeNewswire

PRA Health Sciences, will acquire Symphony Health Solutions

synopsis: PRA Health Sciences, Inc. (“PRA”), a leading clinical research organization, announced it has signed a definitive agreement to acquire Symphony Health Solutions Corporation (“Symphony Health”), a privately-held best-in-class provider of data, analytics and consulting solutions to the life sciences market.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: Symphony Technology Group
target: Symphony Health Solutions
Symphony Health Solutions is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth.
price ($mm)
$530
rev ($mm)
$200
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 3/18/2016 via BNC Analysis

PRA Health Sciences, acquired Nextrials, Inc.

synopsis: PRA Health Sciences acquired all of the outstanding shares of Nextrials, Inc., a developer of web-based software which integrates electronic health records with clinical trials. Nextrials is an innovative, award-winning, leader in web-based software solutions for the clinical research industry.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
At PRA Health Sciences, providing innovative solutions for their clients is what they do. They strive to move drug discovery forward, to help them develop life-saving and life- improving drugs. "
target: Nextrials, Inc.
Nextrials is an innovative, award-winning, leader in web-based software solutions for the clinical research industry. Prism®, the Company’s clinical trial management software, brings together sophisticated trial management and electronic data capture (“EDC”) in a single package.
price ($mm)
$4.70
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/20/2011 via PR Newswire

PRA International, acquired Kinship Technologies Pvt. Ltd.

synopsis: PRA International has acquired Kinship Technologies, a Chennai, India-based software developer and services company. Kinship's flagship product, EXACT, is a revolutionary system that allows users to quickly construct reusable programs for data extraction, data transformation, statistical reporting and electronic publishing.
buyer: PRA International (PRAH:$1,698.48)
PRA International conducts clinical trials across all therapeutic areas in more than 80 countries and provides services in all phases of clinical development through its 40 global offices. "
target: Kinship Technologies Pvt. Ltd.
Kinship Technologies is a leading, global provider of innovative high-quality software products and services that enhance, optimize and accelerate the drug development process from source to submission through integration, automation and effective application of advanced technology solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$9,474.88)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Symphony Health Solutions


read more

Symphony Health Solutions

Lexi-Comp, Inc.

Corrona, Inc.

Cognitive Drug Research, Ltd.

Vidal Group

Shanghai Datong Medical Information Technology Co., Ltd.

Pharmacy OneSource, Inc.

MedAvante, Inc.

BioScriptRx

Kalorama Information

Health Strategies Group

Metanexgen, Inc.

DoctorDirectory.com

Carson Analytics

MD Mindset, LLC

AlphaDetail, Inc.

Bell Falla & Associates LLC

Elsevier Business Intelligence

Rapidata.net, Inc.

IASIST, S.A.

read more

Symphony Health Solutions

read more

Parallel 6

Symphony Health Solutions

Nextrials, Inc.

Kinship Technologies Pvt. Ltd.

read more

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Geography
Matching Companies
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3, Inc.
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet.
year
2019
rev ($mm)
$1,110.45
EBITDA ($mm)
$306.07
EBIT ($mm)
$279.73
Net Income ($mm)
$191.17
Employees
6024
  • drill down
  • watch
Ticker: NYSE:IQV
 
 
 
 
 
 
 
 
IQVIA
IQVIA
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services.
year
2018
rev ($mm)
$10,412.00
EBITDA ($mm)
$1,950.00
EBIT ($mm)
$809.00
Net Income ($mm)
$259.00
Employees
58000
  • drill down
  • watch
Ticker: ENXTPA:CGM
 
 
 
 
 
 
 
 
Cegedim
Cegedim
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases.
year
2018
rev ($mm)
$512.82
EBITDA ($mm)
$50.20
EBIT ($mm)
$33.91
Net Income ($mm)
$6.33
Employees
4468
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
Clarivate Analytics
Clarivate Analytics
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management.
year
2019
rev ($mm)
$964.58
EBITDA ($mm)
$154.61
EBIT ($mm)
($47.97)
Net Income ($mm)
Employees
4515
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2017
rev ($mm)
$3,467.64
EBITDA ($mm)
$637.81
EBIT ($mm)
$406.82
Net Income ($mm)
$252.97
Employees
34651
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch